myotubes (Olympus)
Structured Review
![[¹⁸F]ROStrace uptake in C2C12 <t>myotubes</t> under oxidative stress conditions. ( a ) Time-dependent uptake of [¹⁸F]ROStrace in LPS-treated C2C12 myotubes. Cells were incubated with the tracer for 10, 30, 60, and 120 min, and intracellular radioactivity was measured using a gamma counter ( n = 5 per time point). Uptake is expressed as the percentage of the injected dose per well (%ID). ( b ) Comparative uptake of [¹⁸F]ROStrace after 60 min of incubation in C2C12 myotubes treated with LPS (0.2 mg/mL), or pretreated with N -acetylcysteine (NAC, 3 mM) or piperlongumine (PL, 10 µM). LPS-treated myotubes showed significantly higher uptake than untreated controls ( p = 0.0005, Cohen’s d = 3.54, 95% CI [− 3.627, − 1.509]), while NAC pretreatment reduced tracer uptake ( p < 0.0001, Cohen’s d = 6.51, 95% CI [1.886, 2.974]). PL pretreatment resulted in significantly elevated uptake compared to untreated controls group ( p = 0.0051, Cohen’s d = 2.54, 95% CI [− 4.707, − 1.217]). Data are presented as mean ± standard deviation (SD); n = 5 for all groups.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_3252/pmc12873252/pmc12873252__41598_2026_35489_Fig1_HTML.jpg)
Myotubes, supplied by Olympus, used in various techniques. Bioz Stars score: 99/100, based on 3207 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/myotubes/pmc12873252-181-7-15?v=Olympus
Average 99 stars, based on 3207 article reviews
Images
1) Product Images from "Noninvasive PET imaging of LPS-induced oxidative stress in skeletal muscle using a ROS-targeting radiotracer"
Article Title: Noninvasive PET imaging of LPS-induced oxidative stress in skeletal muscle using a ROS-targeting radiotracer
Journal: Scientific Reports
doi: 10.1038/s41598-026-35489-3
Figure Legend Snippet: [¹⁸F]ROStrace uptake in C2C12 myotubes under oxidative stress conditions. ( a ) Time-dependent uptake of [¹⁸F]ROStrace in LPS-treated C2C12 myotubes. Cells were incubated with the tracer for 10, 30, 60, and 120 min, and intracellular radioactivity was measured using a gamma counter ( n = 5 per time point). Uptake is expressed as the percentage of the injected dose per well (%ID). ( b ) Comparative uptake of [¹⁸F]ROStrace after 60 min of incubation in C2C12 myotubes treated with LPS (0.2 mg/mL), or pretreated with N -acetylcysteine (NAC, 3 mM) or piperlongumine (PL, 10 µM). LPS-treated myotubes showed significantly higher uptake than untreated controls ( p = 0.0005, Cohen’s d = 3.54, 95% CI [− 3.627, − 1.509]), while NAC pretreatment reduced tracer uptake ( p < 0.0001, Cohen’s d = 6.51, 95% CI [1.886, 2.974]). PL pretreatment resulted in significantly elevated uptake compared to untreated controls group ( p = 0.0051, Cohen’s d = 2.54, 95% CI [− 4.707, − 1.217]). Data are presented as mean ± standard deviation (SD); n = 5 for all groups.
Techniques Used: Incubation, Radioactivity, Injection, Standard Deviation
Figure Legend Snippet: Biological and structural alterations in LPS-treated C2C12 myotubes. ( a ) Representative phase-contrast images of C2C12 myoblasts, differentiated myotubes, and LPS-treated myotubes (0.2 mg/mL, 24 h). Scale bar = 100 μm. ( b ) Quantification of myotube width in control and LPS-treated groups ( n = 3, p = 0.0183, Cohen’s d = 3.14, 95% CI [1.537, 9.496]). ( c ) Representative fluorescence images of MitoTracker Red CMXRos-stained myoblasts, myotubes, and LPS-treated myotubes. Scale bar = 100 μm. ( d ) Quantification of MitoTracker fluorescence intensity relative to myoblasts ( n = 3; myoblast vs. myotube, p = 0.0003, Cohen’s d = 9.63, 95% CI [− 66.52, − 41.16]; myotube vs. myotube + LPS, p = 0.009, Cohen’s d = 3.87, 95% CI [14.39, 55.00]). ( e ) Relative mRNA expression levels of MuRF-1 ( p = 0.0454, Cohen’s d = 2.34, 95% CI [− 0.8699, − 0.01472]) and Atrogin-1 ( p = 0.0494, Cohen’s d = 2.28, 95% CI [− 0.3060, − 0.0006591]) in control and LPS-treated myotubes assessed by RT-qPCR ( n = 3). Data are presented as mean ± SD.
Techniques Used: Control, Fluorescence, Staining, Expressing, Quantitative RT-PCR
Figure Legend Snippet: Assessment of ROS levels in C2C12 myotubes using DHE fluorescence. ( a ) Representative fluorescence images of C2C12 myotubes stained with dihydroethidium (DHE; 20 µM, 30 min) in control and LPS-treated groups. Scale bar = 100 μm. ( b ) Quantification of DHE fluorescence intensity. LPS-treated myotubes exhibited increased fluorescence compared to controls, although the difference was not statistically significant ( n = 9, p = 0.0079, Cohen’s d = 1.43, 95% CI [− 131.1, − 23.29]). Data are presented as mean ± standard deviation (SD).
Techniques Used: Fluorescence, Staining, Control, Standard Deviation


